CN106031722A - Composition for treating diseases caused by body and nervous system disorder or inflammation, and applications thereof - Google Patents

Abstract

The present invention provides a composition for treating diseases caused by body and nervous system disorder or inflammation. The composition comprises, by weight, 50-99% of EPA, 1-15% of GLA, absolutely less than 0.3% of DHA, and 0.1-5% of vitamin B, wherein the vitamin B is selected from one or a plurality of materials selected from vitamin B6, vitamin B9 and vitamin B12. The present invention further provides applications of the composition and the preparation thereof in treatment of cardiovascular diseases, anxiety, depression, schizophrenia, autism, Teenagers hyperactivity, inability to concentrate, Alzheimer's disease, and severe neuropathic headache diseases.

Description

The compositions of the disease that treatment health and nervous system disorder or inflammation cause and application

Technical field

The invention belongs to field of pharmaceutical preparations, treat health particularly to one and nervous system loses The compositions of the disease that tune or inflammation cause and application.

Background technology

Essential fatty acid adheres to two groups: Omega-3 (α-linoleic acid) separately and Omega-6 is (sub- Oil olefin(e) acid) family, it is necessary to fatty acid changes into long-chain fatty acid in vivo, and Omega-3 changes into EPA and DHA, Omega-6 change into GAMA-linolenic acid (GLA).

EPA, i.e. eicosapentaenoic acid, be a kind of highly unsaturated fatty acid, can be by diet Basic fatty acid alpha-linolenic acid obtain through third-order reaction.EPA is a kind of containing 20 carbon atoms With the fatty acid of 5 double bonds, all double bonds are cisoid conformation.In human body, alpha-linolenic acid converts Reaction for EPA is more slow, thus the most few part of alpha-linolenic acid taken in diet is turned Chemical conversion EPA；It has also been found that there is EPA in Marine microorganism, and by the transmission of food chain, EPA The natural marine oils obtained in oil-producing Fish and marine mammal accounts for 3%-30%.

DHA, docosahexenoic acid, is a kind of unsaturated fatty acid very important to human body, Belong to the important member in omega-3 unsaturated fatty acid family.DHA is typically at nature with glycerol Three ester forms exist；Marine fishes, some Sargassum or lower fungus are the important sources of DHA.

Existing PCT application file WO98/162176 discloses the oils rich in EPA to treatment spirit Split disease is effective, and the oils rich in relevant fatty acid DHA is not similar to curative effect, and it is also Disclose EPA and derivant thereof the purposes in the treatment of psychotic disorder.

On the basis of the above, patent CN00803202.5 discloses and a kind of easily absorbs shape containing EPA The pharmaceutical preparation of formula, in the fatty acid of this pharmaceutical preparation, EPA content is at least 90%, and DHA Content less than 5%；This pharmaceutical preparation is used for treating spirituality or central nervous system diseases.Pin Ideal basis to EPA and DHA fatty acid, it is found by the applicant that the preparation in this art solutions There are weak point: its pharmaceutical formulation, for being used together with other drug, plays auxiliary treatment and makees With；After take said preparation 3-4 month to patient, generally there is a good curative effect, but spirit disease Disease is often permanence, therefore, psychotic use said preparation time usual Time of Administration very Long more patient to take more than 1 year, and small number of patients then needs to take 2 years, even 3 years Above.So, the EPA of long-term taking high concentration, make Omage-3 and Omage-6 in human body Dysequilibrium, allows people produce the sensation overflow；Therefore, the flat of above-mentioned formulation ingredients is not the most considered Weighing apparatus is its major technique defect, and the therapeutic effect of above-mentioned preparation is the best, and it cannot cause in inflammation Various diseases in carry out medicinal application.

Summary of the invention

In order to solve above-mentioned technical problem, the invention provides one and treat health and nervous system The pharmaceutical preparation of the disease that imbalance or inflammation cause, the preparation of the present invention contains high-purity and concentration Omega-3EPA, its with Omega-6GLA with distinctive formula ratio with the use of, have Good antiinflammatory action, makes the inflammatory conditions of patient be obviously reduced, and neural healthy shape Condition is clearly better；Said preparation does not contains DHA as far as possible, reduces the competition of DHA and EPA Effect；Additionally, add appropriate vitamin B group, make the therapeutic effect of formula more preferably, available There are health and nervous system disorder or because of the disease that inflammation causes in treatment, there is fabulous controlling Therapeutic effect.

The concrete technical scheme of the present invention is as follows:

The present invention provides a kind of and treats health and nervous system disorder or the group of disease that inflammation causes Compound, wherein, described compositions comprises the EPA of the component of following percetage by weight: 50-99%, The GLA of 1-15% and the DHA less than 0.3%.

The amount of the DHA in the present composition is preferably percetage by weight and is less than 0.1%, combination Thing reduces DHA content as far as possible, in order to reduce the Competition of DHA and EPA.

Wherein, the percetage by weight of GLA be preferably 3-10%, Omega-3EPA and Omega-6GLA is used together and can play preferable antiinflammatory action, the EPA of optimization formula amount and The antiinflammatory action of GLA is more preferably.

The compositions of the present invention also includes the vitamin B that percetage by weight is 0.1-5%, described dimension One or more in vitamin B6, FA or vitamin B12 of raw element B.

Preferably, the percetage by weight of vitamin B is 0.6-2%.

Containing vitamin B6, B9 and B12 in the compositions of the present invention, making of vitamin B complex With allowing internal homocysteine be in health level, too high homocysteine not only can Allow cardiovascular system go wrong, be also closely connected together with mental sickness, particularly depression (Am J Psychiatry 2007Jun；164(6):861-7)；Additionally, just prove homotype half in one's early years Theory (the Arch Aeurol:1998 that cystine and senile dementia directly contact；1455. Doi10:1001/archneur.55.11.1449)。

Although the DHA that the internal display of old dementia patients is the lowest, but applicant studies discovery The best approach correcting DHA index is not to supplement DHA simply, and should supply EPA. Have enough EPA if internal, then internal can spontaneous required DHA, it addition, EPA Can the activity of inhibition of phospholipase A 2 because the phospholipase A2 of over-activity be with neurotoxicity, Brain cell death is linked to be together, and brain cell death is that senile dementia is moved back with other nervous tissues Change the feature of disease.

Preferably, the compositions of the present invention contains the composition of following weight:

Preferably in another scheme, the compositions of the present invention contains the composition of following parts by weight:

For these 2 Omega-3 fatty acids of EPA and DHA, as patent document Theory described in CN0083202.5, when EPA and DHA coexists, they tie with competing with one another for Closing the avtive spot of relevant enzyme, therefore DHA can reduce the activity of EPA；For this can be overcome to ask Topic, in the compositions of the present invention, the relative content of DHA is less than 0.3%, preferably less than 0.1%, The preparation technology of the EPA of this purity is troublesome, EPA purifying process be a kind of microalgae and The process of the esterification EPA extracted in fish oil.

The purification schemes of EPA is the wettest or the seaweed bio of lyophilizing or fish oil, and this technique has Three key steps: raw material is extracted and lipid saponification in raw material by (1), fat therein Fat acid is converted into ethyl EPA；(2) the Silver nitrate silica gel column chromatograph method utilizing natural extract obtains Obtain the ethyl EPA of higher concentration；(3) ethyl obtained by column chromatography removal step (2) The pigment of EPA, then utilizes high pressure liquid chromatography method to obtain the final of 90-96% ethyl EPA Preparation.

Wherein, the fatty acid of the EPA form of the present invention can be any form, it can be from In the fish oil of natural form extract, it is also possible to be synthesis EPA, EPA can be ethyl-EPA, Lithium-EPA, monoglyceride EPA, diglyceride EPA, triglyceride EPA or EPA other Esters or salt, or the free acid form of eicosapentaenoic acid.Top quality EPA should be super Pure, it is practically free of any impure material, comprises DHA the most hardly.

GLA can be to extract from plant, it is also possible to is any synthesized form, preferably GLA One or more in borage oil, Radix Oenotherae erythrosepalae oil or seed of black currant oil.

The pharmaceutical preparation being prepared from by above-mentioned composition and adjuvant, this pharmaceutical preparation can be soft The dosage form of sugar, soft capsule, tablet or oral liquid.

Adjuvant in said medicine preparation includes vitamin E, as antioxidant.

Another aspect of the present invention additionally provides above-mentioned treatment health and nervous system disorder or inflammation is drawn The compositions of disease that rises or pharmaceutical preparation treatment cardiovascular disease, anxiety neurosis, depression, Schizophrenia, infantile autism, juvenile active disease, impotentia are focused on, senile dementia And the medicine of serious neurological headache disease is applied.

In the application of this pharmaceutical preparation, further define the optimal dose that patient takes, instant The compositions that user every 60kg body weight is taken every day contains:

EPA 1200-2000mg

GLA 50-150mg。

The dose of the most described EPA is the dose of 1200mg, GLA when being 88mg, controls Therapeutic effect is optimal.

Further, the compositions that eater every 60kg body weight is taken every day possibly together with:

Vitamin B6 8-24mg

FA 0.3-0.9mg

Vitamin B12 0.3-0.9mg.

Wherein, the compositions of above-mentioned dose treat illness be schizophrenia time, eater Need continuous drug administration more than 2 years.

The dose of the most described vitamin B6 is 8mg, and the dose of FA is 0.3mg, when the dose of vitamin B12 is 0.3mg, therapeutic effect is optimal.

When treating senile dementia, the dose of eater every 60kg body weight every day is:

This dose treatment senile dementia has optimal curative effect.

As previously described, the pharmaceutical formulation of the present invention can treat a lot of physiology and mental illness, These physiology and mental illness have the common ground of some, are i.e. caused by inflammation, are also simultaneously Owing to the ratio imbalance of Omega-3 and Omega-6 in health causes.Omega-3 and Omgea-6 is the fatty acid that 2 species diversity are bigger, and the fatty acid of these 2 families is mutual in human body Competition ground occupies internal limited biochemical enzymes of the same race and micronutrient mutually.Healthierly The ratio of Oomgea-3/Omega-6 about at 1:2, but due to the dietary habit of society now (unsound fast food) allows this ratio more than 1:20 in a lot of human bodies, causes serious The ratio of Omega-3/Omega-6 is uneven.

Too much Omega-6 can cause the imbalance of internal inflammatory reaction because Omega-3 and The fat of Omega-6 is the pioneer of a kind of hormonal substances eicosanoids, class Semen arachidis hypogaeae In acid substance can control human body, inflammatory reaction the most normally works, and the balance of these 2 kinds of fatty acids is certainly The ability controlled inflammation in having determined human body.

Except inflammation control, the kind of Omega-3 and Omega-6 existed in cell membrane and Quantity determines cellularity and intercellular trafficking signal, supplements human vas and central nervous system The ability of the normal work of system.

Omega-6 fatty acid, by numerous intermediate, is finally essentially converted to AA (Semen arachidis hypogaeae Tetraenoic acid), AA is the eicosanoid proinflammatory factor of principal agent, has a large amount of Omega-6 as internal, Omega-6 can be allowed to have monopolized the biochemical enzymes that originally can be simultaneously used in Omega-3 and Omega-6 And micronutrient.This state can increase AA and thing followed inflammatory products.

In turn, if we use enough Omega-3 when diet, then biochemical Process can easily tend to the convert fatty acids of the Omega-3 extracted in the plant of short chain is become long EPA and DHA of chain, the conversion chain promoting Omega-6 was just stopped before becoming AA by this ?.

GLA was first converted to DGLA (dihomo-GLA), DGLA before being transformed into AA Being a key point, it may be transformed into AA from this point on, it is also possible to be transformed into the class of himself Eicosanoids, this material is main anti-inflammation, sees accompanying drawing 1.

It is found by the applicant that the ratio of the EPA of AA and Omega-3 of Omega-6 can be more accurately The health level that one people is overall is described.Suitably supplement GLA and can play GLA's Yu EPA Synergism, the common binding capacity jointly reducing inflammation point AA, promote cell health, reduce The generation of various chronic diseases.This kind of chronic disease include cardiovascular disease, anxiety neurosis, depression, Schizophrenia, infantile autism, juvenile active disease, impotentia are focused on, senile dementia And serious neurological headache disease etc..

Accompanying drawing explanation

Fig. 1 is the transformation process of the ALA of AA and Omega-3 of Omega-6.

Detailed description of the invention

Embodiment 1 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

EPA 1200mg

GLA 88mg

Wherein EPA is the ethyl EPA of 1200mg.

Embodiment 2 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Wherein EPA is the ethyl EPA of 1200mg.

Embodiment 3 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Wherein EPA includes the ethyl EPA of 1200mg.

Embodiment 4 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Wherein EPA includes triglyceride EPA and 650mg of ethyl EPA, 350mg of 200mg Monoglyceride EPA.

Embodiment 5 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Borage oil wherein contains the GLA of 88mg；EPA include 1000mg lithium-EPA, Other suitable forms of the EPA of 200mg.

Embodiment 6 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Borage oil wherein contains the GLA of 88mg；EPA include 600mg ethyl EPA, Lithium-the EPA of diglyceride EPA and 350mg of 250mg.

Embodiment 7 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Borage oil wherein contains the GLA of 62mg；EPA include 800mg ethyl EPA, Lithium-the EPA of diglyceride EPA and 350mg of 250mg

Embodiment 8 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Borage oil wherein contains the GLA of 26.5mg；Containing 31mg's in seed of black currant oil GLA；EPA is ethyl-EPA.

Embodiment 9 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Embodiment 10 compositions

The compositions of the present embodiment is grouped into by the one-tenth of following weight:

Embodiment 11 soft capsule

The soft capsule of the present embodiment is by the compositions of embodiment 2 and diluent, chelating agen, surface Activating agent is core, makes the softgel shell of capsule with soft or hard gel, and is added by fill by core Enter in softgel shell, prepare the fish-oil capsule containing 300mg or 1200mgEPA.

Comparative examples 1

The medicine of the present embodiment is grouped into by the one-tenth of following weight:

EPA 1200mg

Wherein EPA is the ethyl EPA of 1200mg.

Test example 1 vitamin B6, B9 and B12 are on homocysteine and the impact of carotid atherosclerotic plaque Process of the test: using the homocysteine patient more than 14mol/L as subjects, is administered Front detect the carotid atherosclerotic plaque meansigma methods of subjects is 0.21 ± 0.41cm²/ year.

Give subjects eat every day the FA of 2.5mg, 25mg vitamin B6 with And the vitamin B12 of 0.25mg, taking the course for the treatment of is 1 year；Subsequently, the neck of subjects is detected Artery plaque meansigma methods is 0.0491 ± 0.24cm²/ year.

Experimental result: result shows, takes the carotid artery speckle of the patient of vitamin B6, B9 and B12 The rate of growth of block substantially reduces；Additionally, from document Van den Berg M et disclosed in nineteen ninety-five Al.1995 reports, vitamin B group can reduce homocysteine, has further demonstrated that interpolation The invention formulation having vitamin B group makes internal homocysteine for health status, keeps away Exempt from the generation of the mental sickness caused because of too high homocysteine.

The case checking of seriousness long-lasting nerve headache is treated in analysis of cases 1

1. test case

Accepting patient's totally 103 example for medical treatment, the age all, between 25-70 year, is diagnosed as seriousness the most refreshing Through property headache and migraine, the common ground of this crowd of patient is per week will to violate serious headache (migraine), majority, after using the maximum amount of analgesic, are still difficult to their serious head Pain is stopped.

2. packet and administration

The patient of 103 example seriousness long-lasting nerve headaches and migraine is randomly divided into A group 52 examples, B group 51 example；A group takes the medicine of comparative examples 1, and B group is taken The compositions of embodiment 1, is administered 3 months, once a day.

3. observational technique

Each patient the most all records medical history, sign, diagnosis, painful area and character and relevant Physics, physiology inspection.

4. result

2 groups of patients are after taking corresponding medicine 3 months, and the feedback of A group patient is that headache alleviates 70-80%, also needs to a small amount of analgesic once in a while and controls during treatment, or needs to execute EPA dosage be increased to 2g from 1200mg.The feedback of B group patient is that headache alleviates 80-90%, need not during treatment control with analgesic.

5. conclusion

The composite formula that the present invention provides can be used for treating seriousness long-lasting nerve headache, only Effect bitterly is better than simple EPA medicine, and during verifying its curative effect, does not finds any Untoward reaction.

The case checking of juvenile hyperkinetic syndrome is treated in analysis of cases 2

1. test case

Accepting patient's totally 50 example for medical treatment, the age all, between 12-13 year, is diagnosed as and suffers from active disease, Showing as concentrating one's energy, this crowd of patient attends of Special care (love especially) School.

2. packet and administration

The patient that 50 examples are suffered from juvenile hyperkinetic syndrome is randomly divided into A group 25 example, B group 25 example；A Group takes the medicine of comparative examples 1, and B group takes the compositions of embodiment 2, It is administered 6 months, once a day.

3. observational technique

Each patient the most all records medical history, observes its behavior act through the head of a family or teacher, note Meaning power integrated test is given a mark, and does relevant physics, physiology inspection.

4. result

2 groups of patients are after taking corresponding medicine 3 months, and the evaluation that the head of a family gives with teacher is similar, All giving and improve the scoring that effect is 70-75, the active disease of these 2 groups of children well changes, Also show as study of preferably concentrating one's energy simultaneously.

After taking 6 months, the head of a family of A group child reflect child after taking 4 months just to height The use of concentration EPA produces " resistance ", and improvement degree rests on 70-75 and divides；The child of B group The formulation efficacy of the compositions of the present invention is felt quite pleased by the head of a family, comments except 4 children improve degree Dividing rests on outside 75, and the improvement of other the head of a family is marked all at 80-85, has changing of 3 children Kind scoring is 90 points.

5. conclusion

The composite formula that the present invention provides can be used for treating juvenile active disease, improves effect ratio single Pure EPA medicine is good, and during verifying its curative effect, does not finds any untoward reaction.

The case checking of depression is treated in analysis of cases 3

1. test case

Accepting patient's totally 42 example for medical treatment, the age all, between 14-50 year, is diagnosed as manic depression, Owing to enduring conventional medicament side effects to the fullest extent, all showing as body weight increases, and libido disappears, whole body Numb.

2. packet and administration

The patient that 42 examples suffer from depression is randomly divided into A group 21 example, B group 21 example；A group is given Giving the medicine taking comparative examples 1, B group takes the compositions of embodiment 2, is administered 6 Individual month, once a day.

3. observational technique

Each patient the most all records medical history, observes its life emotional state, exchanges with patient, And do relevant physics, physiology inspection.

4. result

2 groups of patients, after taking corresponding medicine 3 months, allow each patient change the state of oneself It is apt to give a mark, is specially and puts question to: if you are before accepting this Therapeutic Method before 3 months, Your manic phase is " terrifying waves ", and after 3 months, you feel that the degree improved is how many points？A The improvement of group answer is equally divided into 72 points, and the improvement of B group answer is equally divided into 74 points.

After taking 6 months, allowing patient oneself mark again, the adult of A group is reflected in 4 After individual month, then eat the sensation that high-purity EPA medicine is generation detest, be unwilling to take again. The composition effect of the present invention is satisfied with by B group adult.A group patient when 6 months to him To improve mean scores be 78 points；And the average mark of B group is 86 parts, wherein there are two patients Give the score value of 95 points.

5. conclusion

The composite formula that the present invention provides can be used for treating depression, improves effect ratio simple EPA medicine is good, and during verifying its curative effect, does not finds any untoward reaction.

The case checking of senile dementia is treated in analysis of cases 4

1. test case

Accept patient's totally 10 example for medical treatment, the age all between 60-85 year, the old man of nest egg institute, really Examine and suffer from senile dementia.The dementia degree of patient is similar, their common ground be have higher Homocysteine, having is not the most serious understanding defect, and these 10 old men can recognize Know the face of the relatives (old man and child) of oneself, but their name the most wrong, Do not remember their birthday.

2. packet and administration

The patient that 10 examples suffer from depression is randomly divided into A group 5 example, B group 5 example；A group gives Taking preparation prepared by the compositions of comparative examples 1, B group takes the group of embodiment 3 Compound, is administered 6 months, once a day.

3. observational technique

Each patient the most all records medical history, observes its life emotional state, exchanges with patient, Whether remembered name and the birthday of relatives by inquiry old man, and add up its memory number of times.

4. result

2 groups of patients are after taking corresponding medicine 3 months, and nursing staff and family members generally believe this The emotion of group old man is improved, and language starts many, but in memory on not the biggest changing Kind.After taking 6 months, having done identical investigation, old man's memory situation is improved.Its Result statistics is shown in Table 1.

Table 1 take medicine after old man's memory state statistical table

Result shows, when 6 months, A group had the obvious memory of old man slightly to move back Step, other four old men with 3 months time memory very close to.B group old man family members and nursing Personnel reflect that five old men of B group forgetful phenomenon in daily life significantly improves, they Think and at least improve about 10%；Additionally B group also inspirer phenomenon is, each The accuracy that the name of relatives is remembered by old man at least increases 2 times, and B group has two old man's energy one The secondary birthday quoting their child.

5. conclusion

The composite formula that the present invention provides can be used for treatment initial stage senile dementia, improves effect Better than simple EPA medicine.The particularly composite formula of embodiment 2, best results, should Formula has a bigger breakthrough to the patients of senile dementia of first stage, and can control this kind of always People is developed to second stage.Additionally, the compositions of the present invention is during verifying its curative effect, not Find any untoward reaction.

Model case

1, the treatment of cardiovascular disorder

Patient is the girl of 11 years old, is diagnosed as the rare cardiovascular disorder that rheumatic fever causes, special Levying is the permanent scar of heart Bicuspid valve that causes of rheumatic fever, and this scar makes mitral organ become Obtain narrow, the most even can not be normally carried out closing up.The heart even can be caused during this serious symptom Dirty blood back flow.

The formula treatment of the embodiment 2 of the application of the invention, the course for the treatment of is 10 months, patient's Bicuspid valve organ state is obviously improved, and Bicuspid valve can the most normally close up, patient's holistic health And self-confidence is also greatly enhanced.

2, the treatment of anxiety, panic disorder

Patient is the middle-aged and elderly people of 53 years old, suffers from Anxiety disorders more than 2 years, show as nervous, Anxiety, usually baffled in terror because of minor matter, the palm of the hand is perspired in a large number, and every day all can occur about 3 hours Whole body feel nervous, it is impossible to sit idly, can only be by carrying out keeping tensions down symptom the most on foot.

The capsule that patient uses embodiments of the invention 2 compositions to prepare is treated, and takes one After week, anxiety, panic disorder are clearly better, and continue edible 3 months, and the anxiety of patient is shied Probably emotion is controlled, and palm of the hand perspiration and the situation that cannot sit idly also are wholly absent.

3, the treatment of heart schizoaffective disorder

Patient is the male of 51 years old, is diagnosed as schizophrenia, and it takes clozapine medicine 3 years Many, the state of an illness obtains basic controlling；But clozapine medicine allow patient be in all day tired unable, Downhearted state.

Advising through household, patient takes preparation prepared by the embodiment of the present invention 2 compositions.Patient After taking 10 days, its schizoaffective disorder is still controlled, and the mental status substantially ratio is before Taking a favorable turn, then, patient has suspended the edible of clozapine medicine, and continues the edible present invention's Preparation；Through the treatment of nearly 4 months, patient household observe its mental status of evaluation than Before be clearly better；When continuing to take 8th month, the overall mental status of patient basically reaches The spiritual standard of one normal person, compared with the state that he is initial, family numbers of patients think its When taking 8 months, patient condition achieved with about 80% improvement.

Claims (25)

1. treat health and nervous system disorder or a compositions for disease that inflammation causes, wherein, Described compositions comprises the EPA of the component of following percetage by weight: 50-99%, 1-15%'s GLA and the DHA less than 0.3%.

2. compositions as claimed in claim 1, the percetage by weight of wherein said DHA is less than 0.1%.

3. compositions as claimed in claim 1, the percetage by weight of wherein said GLA is 3-10%.

4. the compositions as according to any one of claim 1-3, described compositions also includes weight hundred Mark is the vitamin B of 0.1-5%；Described vitamin B is selected from vitamin B6, vitamin One or more in B9 or vitamin B12.

5. compositions as claimed in claim 4, the percetage by weight of wherein said vitamin B is 0.6-2%.

6. compositions as claimed in claim 5, described compositions contains the component of following weight:

7. compositions as claimed in claim 5, described compositions contains the component of following weight:

Compositions the most as described in any of claims 1, wherein said EPA be ethyl-EPA, Lithium-EPA, monoglyceride EPA, diglyceride EPA, triglyceride EPA or EPA other Esters or salt, or the free acid form of eicosapentaenoic acid.

9. compositions as claimed in claim 1, wherein said GLA is selected from borage oil, Radix Oenotherae erythrosepalae One or more in oil or seed of black currant oil.

10. the medicine system being prepared from by the compositions according to any one of claim 1-9 and adjuvant Agent, wherein said pharmaceutical preparation can be the preparation of soft sweet, soft capsule, tablet or oral liquid Form.

11. pharmaceutical preparatioies as claimed in claim 10, described adjuvant includes vitamin E.

The compositions of 12. arbitrary aforementioned claim or pharmaceutical preparation are at treatment health and nervous system Purposes in the medicine of the illness that imbalance or inflammation cause.

13. purposes as claimed in claim 12, described illness is cardiovascular disease.

14. purposes as claimed in claim 12, described illness be anxiety neurosis, juvenile active disease with And impotentia focuses on disease.

15. purposes as claimed in claim 12, described illness is depression or infantile autism.

16. purposes as claimed in claim 12, described illness is serious neurological headache.

17. purposes as claimed in claim 12, described illness is schizophrenia.

18. purposes as according to any one of claim 13-17, the every 60kg of wherein said eater The compositions that body weight is taken every day contains:

EPA 1200-2000mg

GLA 50-150mg。

19. purposes as claimed in claim 18, the dose of wherein said EPA is 1200mg, The dose of described GLA is 88mg.

20. purposes as claimed in claim 18, wherein said eater every 60kg body weight clothes every day Compositions possibly together with:

Vitamin B6 8-24mg

FA 0.3-0.9mg

Vitamin B12 0.3-0.9mg.

21. purposes as claimed in claim 20, the dose of wherein said vitamin B6 is 8mg, the dose of described FA is 0.3mg, the dose of described vitamin B12 For 0.3mg.

22. purposes as claimed in claim 20, when treatment illness is schizophrenia, described food The continuous drug administration of user was more than 2 years.

23. compositionss as according to any one of claim 4-7 are in the illness for the treatment of senile dementia Purposes in medicine.

24. purposes as claimed in claim 23, taking of described eater every 60kg body weight every day Amount is:

The preparation method of the EPA described in 25. 1 kinds of claim 1, comprises the following steps:

(1) extracting raw material and lipid saponification in raw material, convert fatty acids therein is Ethyl EPA；

(2) the Silver nitrate silica gel column chromatograph method utilizing natural extract obtains the ethyl of higher concentration EPA；

(3) pigment of the ethyl EPA obtained by column chromatography removal step (2), then profit The final preparation of 90-96% ethyl EPA is obtained by high pressure liquid chromatography method；

Wherein, raw material is seaweed bio or the fish oil of wet lyophilizing.